Weill Cornell Medicine has received $4.2 million to study how the immune system in some people infected with HIV can keep the virus under control, which could lead to new therapies.
Researchers at Weill Cornell Medicine have used machine learning to define three subtypes of Parkinson’s disease based on the pace at which the disease progresses.
A new consortium co-led by Weill Cornell Medicine has been awarded a five-year, $31 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to accelerate the development of better treatment regimens for tuberculosis.
Scientists from Weill Cornell Medicine and the Dana-Farber Cancer Institute have developed new AI tools tailored to digital pathology, a growing field that uses high-resolution digital images created from tissue samples to help diagnose disease.
Vaccinating mothers against RSV during late pregnancy to protect their newborns is not associated with an increased risk of preterm birth or other poor outcomes, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.
A multinational team led by Weill Cornell Medicine investigators developed a test for an HIV strain that disproportionately affects women and will benefit patients around the world.
ACT for Youth, which promotes adolescent health and well-being in New York state, has been awarded $5 million to help local health departments improve care for youth with special needs.
Before a cell commits fully to the process of dividing itself into two new cells, it may ensure the appropriateness of its commitment by staying for many hours – sometimes more than a day – in a reversible intermediate state, according to new research.
Michael I. Kotlikoff assumes the role of Cornell’s interim president following the retirement of Cornell’s 14th president, Martha E. Pollack. He will serve until 2026.
